The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Phase
Observational
Started
2025-05-10
Last updated
2026-07-06
Condition(s) studied
KeloidsFibroblast
Investigational drug(s) / intervention(s)
Tissue Collection
Tissue Collection: Surgical tissue collection only, no intervention
Study summary
Keloids are benign fibroproliferative skin disorders characterized by excessive fibroblast activation and extracellular matrix deposition. The molecular mechanisms underlying keloid formation remain incompletely understood. This prospective observational study aims to investigate the biological characteristics of keloid tissue by comparing surgically resected keloid specimens with adjacent normal skin obtained from the same patients. Histological and molecular analyses, including histopathology, polymerase chain reaction (PCR), Western blotting, and related laboratory assays, will be performed to identify signaling pathways and key regulatory factors associated with fibroblast activation. The findings may improve the understanding of keloid pathogenesis and identify potential therapeutic targets for future treatment.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria:
* Clinically diagnosed with keloid.
* Age 18 years or older.
* Scheduled to undergo surgical treatment at the study hospital.
* Able and willing to provide written informed consent.
Exclusion Criteria:
* Severe systemic disease.
* History of neurologic disease, alcoholism, postherpetic neuralgia, HIV infection, hypothyroidism, diabetes mellitus, or prior cancer chemotherapy.
* Other skin diseases within 5 cm of the keloid lesion, such as eczema.
* Systemic treatment within 7 days before enrollment or keloid-specific treatment within 6 weeks before enrollment, including intralesional corticosteroid injection, cryotherapy, topical medication, or silicone gel sheeting.
* Hormone or immunosuppressive therapy within 3 months before enrollment.
* Pregnancy or breastfeeding.
* Considered unsuitable for participation by the investigator.
* Refusal to participate in the study.
Primary outcome measure(s)
Expression Levels Of Fibrosis-Related Markers — Up to 2028 Comparison of expression levels of fibrosis-related and fibroblast activation markers (including TGF-β, α-SMA, collagen I, and related signaling molecules) between keloid tissue and adjacent normal skin using PCR, Western blot, and histological analysis.
Trial sites (1)
Facility
City
Region
Status
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Jinhua
China
Recruiting
More The Fourth Affiliated Hospital of Zhejiang University School of Medicine trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.